Drug Discovery Informatics Market By Product Type, By Manufacturers, By End-User And Market Trend Analysis Forecast 2033

The Drug Discovery Informatics by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Drug Discovery Informatics Market:

https://www.thebusinessresearchcompany.com/report/drug-discovery-informatics-global-market-report

According to The Business Research Company’s Drug Discovery Informatics, The drug discovery informatics market size has grown rapidly in recent years. It will grow from $3.36 billion in 2023 to $3.77 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to genomics and proteomics advancements, increasing complexity of drug targets, advancements in structural biology, rise in outsourcing, pharmacogenomics integration, drug repurposing strategies..

The drug discovery informatics market size is expected to see rapid growth in the next few years. It will grow to $6.06 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to expansion of precision medicine, drug-drug interaction prediction, patient-derived data analysis, biosimilars development, growing number of drug candidates.. Major trends in the forecast period include ai and machine learning integration, digital twins in drug development, collaboration platforms, blockchain for data security, advancements in imaging technologies, cloud-based informatics platforms..

The rising prevalence of various chronic diseases is expected to propel the growth of the drug discovery informatics market going forward. Chronic illnesses are described generically as disorders that persist for a year or longer and need continuing medical treatment, impede everyday activities or both. Drug discovery informatics systems aid in the advancement of chronic illness care by allowing researchers to probe more complex and transient molecular changes that underpin disease progression and drug response, resulting in multi-dimensional models of the entire hierarchical system in healthy, diseased, and treated states. For instance, according to a report published by the World Health Organization, a Switzerland-based agency of the United Nations responsible for international public health, in 2022, non-communicable diseases (NCDs) are expected to kill 41 million people, accounting for 74% of all deaths worldwide. Every year, 17 million people die from an NCD before the age of 70, with low- and middle-income nations accounting for 86% of these premature fatalities. Cardiovascular illnesses kill the most individuals each year (17.9 million), followed by cancer (9.3 million), chronic respiratory disorders (4.1 million), and diabetes (2.0 million, including kidney disease deaths caused by diabetes). Therefore, the rising prevalence of various chronic diseases is driving the growth of the drug discovery informatics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=8960&type=smp

The drug discovery informatics market covered in this report is segmented –

1) By Service: In-House, Outsourced

2) By Modality: Cloud-Based Systems, In-Campus

3) By Application: Data Sequencing, Molecular Docking, Identification And Validation, Target Data Analysis

4) By End-User: Pharmaceutical Companies, Contract Research Organizations, Bio-Technology Companies

Technological advancements have emerged as a key trend gaining popularity in the drug discovery informatics market. Major companies operating in the drug discovery informatics market are focused on developing technologically advanced solutions to sustain and strengthen their market position. For instance, in January 2021, Certara Inc., a US-based biosimulation company introduced version 20 of its Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform. It provides new and improved maternal health models, such as measuring medicine performance during pregnancy and lactation. The Simcyp PBPK Simulator enhances clinical trial efficiency and results by modelling and simulating pharmacokinetics (PK) and pharmacodynamics (PD) using virtual patient populations. For biological drug development, it employs the predictive pharmacokinetics of small molecules.

The drug discovery informatics market report table of contents includes: